A COMPARATIVE STUDY ON PHARMACOECONOMIC ANALYSIS OF RHEUMATOID ARTHRITIS PATIENT IN TWO DIFFERENT HOSPITALS IN TAMIL NADU
DOI:
https://doi.org/10.22159/ijpps.2020v12i2.35935Keywords:
Rheumatoid arthritis, DMARDs, Cost of illness, Comparison of prescribing pattern of two groupsAbstract
Objective: The objective of the present study is to compare the prescribing patterns and cost of illness of Rheumatoid arthritis patients in two different hospitals.
Methods: This is an observational study conducted in two different tertiary care hospitals in Salem district after obtaining approval of the Institutional Ethics Committee (IEC) (Registration Number EC/PHARM D/2019.06). A sample size of 102 (above 18 y) patients were included (52 from group 1 hospital and 50 from group 2 hospital). The study was conducted over a period of 6 mo from February 2019 to July 2019. The cost was collected by a patient face-to-face interview.
Results: Out of 102 patients, females (57.84%) patients were more prevalent than men with the age group of 50-59 y in both groups. Methotrexate was most commonly prescribed drug in group 1(36.5%), whereas in group 2 are Sulfasalazine (37%). Among the DMARDs unit cost of methotrexate is high but the monthly cost was high for Sulfasalazine, because the methotrexate is prescribed on a once-weekly basis while sulfasalazine is taken twice a day. The cost of NSAIDs comes around 46.47% of the total drug cost of the month. In steroids, cost comes around 11.73% of the total drug cost. Among the direct cost of two groups, the drug cost and transportation cost is higher when compared with other costs. Indirect costs such as lost wages, due to disease is higher in group 1.
Conclusion: The study concluded that the burden of RA to the patient is huge, Appropriate standard prescribing guidelines should be developed and implementation of the rational drug must be promoted. Polypharmacy was reported in group 1 hospital, the progression of symptoms was the same in both hospitals, it increases the cost of therapy and overall cost of patients. Hence it becomes vital to diagnose and control the disease at an early stage to control the economic burden on the patient.
Downloads
References
Roger Walker, Cate Whittlesea. Clinical pharmacy and therapeutic. 5th Edition; 2012.
Vidya Alex, Sumitha Cheruvallikattil, Suja Abraham, Bincy Varghese. Cost of illness of rheumatoid arthritis in south India. World J Pharm Res 2015;11:1305-16.
Kashefi, Saeid, Sang Min Lee, Surulivelrajan Mallaysamy, Girish Thunga P. Demographic, clinical characteristics and drug prescription pattern in patients with rheumatoid arthritis in south indian tertiary care hospital. Int J Pharm Pharm Sci 2016;8:251-7.
Tugwell P. Pharmacoeconomics of drug therapy for rheumatoid arthritis. Rheumatology (Oxford) 2000;39:43-7.
Saptarini, Nyi Mekar, Marlia Singgih Wibowo, Tutus Gusdinar. Correlation study of age, disease duration, and erythrocyte sedimentation rate among the indonesian rheumatoid arthritis patients. Int J Pharm Pharm Sci 2015;7:274-7.
Gawde SR, Shetty YC, S Merchant, Kulkarni UJ, Nadkar MY. Drug utilization pattern and cost analysis in rheumatoid arthritis patients, a cross-sectional study tertiary care hospital. Br J Pharm Res 2013;3:37-45.
Nagappa, Khera K, Rau NR. Pharmacoecnomic and health-related quality of life in rheumatoid arthritis (RA) patients in tertiary care hospital. Karnataka 2013:A1-A298. Doi:10.1016/j.jval.2013.03.1128
Chuanhui XU, Xiuru Wang, Rong MU. Societal cost of rheumatoid arthritis in china: a hospital-based cross-sectional study. Arthritis Care Res 2014;66:523-31.
Sukhpreet, Agarwal V, Tiwari P. Treatment and monitoring costs in rheumatoid arthritis: preliminary results from an Indian setting. Indian J Pharm Sci 2007;69:226-31.
Cooper NJ. Economic burden of rheumatoid arthritis. A systematic review. Rheumatology 2000;39:28-33.
Published
How to Cite
Issue
Section
